PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical [...]

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

Cara Therapeutics (Tarrytown, NY) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation has closed a $24M Series C financing. Investors included Scottish Widows Investment Partnership, Mitsubishi International Corporation, MVM Life Science Partners, Alta Partners and Ascent Biomedical Ventures.

CicuLite (Hackensack, NJ) a medical device company focused on the development of a proprietary circulatory assist technology for the management of chronic heart failure, closed a $20M Series B. Investors included Forbion Capital Partners, Oxford Biosciences Partners, Foundation Medical Partners, and SB Life Science Ventures.

Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.

Critical Biologics (Cambridge, MA) developer of therapeutics for critical-care patients with low plasma gelsolin, has raised $7 million in Series A funding from Morningside Ventures.

BioBehavioral Diagnostics (Cambridge, MA) a developer of a diagnostic system for measuring the core components of Attention Deficit Hyperactivity Disorder closed a $8.5M Series A financing. The deal was led by Sevin Rosen Funds and Tullis-Dickerson.

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.

Ception Therapeutics (Malvern, PA) a drug company developing anti-inflammatories, raised a $63M Series C round. The financing was led by Essex Woodlands Health Ventures, and was joined by Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.

Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.